Company intelligence / Profile preview
Meyer Pharmaceuticals Ltd.
Tuen Mun, New Territories, Hong Kong SAR Chinameyerpharm.com.hk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has sponsored at least one Phase 2 clinical trial comparing systemic chemotherapy to immunotherapy in unresectable/metastatic pancreatic cancer. Another drug candidate, MP–8 targeting MMP8 for arthritis, appears to be in preclinical or pending status. No published results from completed pivotal trials were found.
- Therapeutic areas
- OncologyRheumatology
- Modalities
- Small molecules (based on pipeline drug MP-8)possible biologics/immunotherapies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Meyer Pharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meyer Pharmaceuticals Ltd..